NeuroPace, Inc.

NASDAQ:NPCE

Medical - Devices

Healthcare
$8.22 +0.30%

+$0.05 today

Market cap
$283.19M
Beta
1.88
P/E (TTM)
-23.8
EPS (TTM)
-$0.64
52W Low $7.56High $19.60

Volume 0.31M

Average 0.18M

NPCE Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

NeuroPace, Inc.NASDAQ: NPCE

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development dips below year-ago levels

Q1 FY2026 research & development of $7.19M fell 3.4% year over year, behind the +9.2% change in trailing-twelve-month research & development. Sequentially, it rose 2.3% from the prior quarter. Over 3 fiscal years it compounded at +8.3% a year.

Context

  • Research & development amounted to 27.9% of revenue in FY2025, down 1.7 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -3.4% toward the trailing-twelve-month pace of +9.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.19M+2.3% QoQ
Last fiscal yearDec 2025
$27.89M+17.9% YoY
LTMMar 2026
$27.64M+9.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.4%——
1 year+17.9%——
3-year CAGR+8.3%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
27.89M USD
Year-over-year change
+17.9%
4-year CAGR
+11.2%

Research & Development vs competitors

How NPCE compares with its peers on the latest reported figures

  • NPCE's LTM Mar 2026 research & development of $27.64M is the highest of the 2 companies compared; the peer median is $11.7M.
  • Its year-over-year change of +9.2% is the lowest of 2, against a peer median of +10.5%.
  • Research & development amounts to 27.8% of revenue for NPCE, versus a peer median of 19.8%.
NPCE Competitors Peer median
Research & Development for NPCE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NPCENeuroPace, Inc.LTM Mar 2026$27.64M +9.2%+8.3%27.8%
CVRXCVRx, Inc.LTM Mar 2026$11.7M +10.5%+3.8%19.8%
MOBIMobia Medical, Inc. Common Stock—— ———
Peer median (excluding NPCE) $11.7M+10.5%+3.8%19.8%

Competitors are the stored peer set for NPCE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue45.18M45.52M65.42M79.91M99.99M
Cost of Revenue11.75M13.03M17.3M20.82M22.77M
Gross Profit33.44M32.49M48.12M59.09M77.22M
Gross Margin74.0%71.4%73.6%73.9%77.2%
Research & Development18.21M21.95M20.78M23.65M27.89M
Selling, General & Admin38.96M51.34M54.52M57.1M65.67M
Operating Expenses57.17M73.29M75.3M80.76M93.56M
Depreciation & Amortization296K2.99M1.61M1.77M1.95M
EBITDA(28.37M)(36.57M)(22.83M)(16.57M)(12.06M)
EBITDA Margin-62.8%-80.3%-34.9%-20.7%-12.1%
Operating Income(23.74M)(40.79M)(27.17M)(21.67M)(16.34M)
Operating Margin-52.5%-89.6%-41.5%-27.1%-16.3%
Interest Income448K1.58M3.05M3.02M2.82M
Interest Expense7.41M7.53M8.52M8.8M7.46M
Other Income / Expenses(12.34M)(6.29M)(5.78M)(5.47M)(5.13M)
Income Before Tax(36.08M)(47.08M)(32.96M)(27.14M)(21.47M)
Pre-Tax Margin-79.9%-103.4%-50.4%-34.0%-21.5%
Income Tax Expense00000
Net Income(36.08M)(47.08M)(32.96M)(27.14M)(21.47M)
Net Margin-79.9%-103.4%-50.4%-34.0%-21.5%
EPS (Basic)(2.17)(1.91)(1.27)(0.93)(0.66)
EPS (Diluted)(2.17)(1.91)(1.27)(0.93)(0.66)
Weighted Avg Shares16.61M24.59M25.85M29.13M32.72M
Weighted Avg Shares (Diluted)16.61M24.59M25.85M29.13M32.72M

NeuroPace, Inc.

NASDAQ:NPCE

Intrinsic Alpha fair value

Locked

Current Price

$8.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.